文拉法辛缓释片与黛立新治疗COPD伴焦虑抑郁症患者的疗效观察

Therapeutic effect of venlafaxlna sustained-release tablets and denixit in the treatment of COPD patients with anxious and depressive symptoms

目的探讨文拉法辛缓释片对COPD患者焦虑、抑郁症状的治疗作用。方法将78例COPD合并焦虑、抑郁的老年患者按就诊顺序随机分为研究组39例和对照组39例,两组患者分别予文拉法辛缓释片及黛力新治疗6周观察。用汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD-17)评定疗效,采用症状量表(TESS)评定不良反应。结果治疗6周末,研究组有效率为92.31%,对照组有效率为66.67%,两组比较差异有统计学意义(χ2=4.27,P<0.05)。两组不良反应TESS评分比较差异有统计学意义(t=5.75,P<0.05),研究组不良反应明显较少。结论文拉法辛缓释片为一种安全有效和耐受性良好的抗焦虑、抑郁药物。

Objective To investigate the efficacy and effects of venlafaxlna sustained-release tablets and denixit in the treatment of COPD patients with anxious and depressive symptoms.Methods According to hospitalization sequence,78 of COPD patients with depressive symptoms were randomly divided into two groups,the study group（n=39,treated with venlafaxlna sustained-release tablets for 6 weeks） and the control group（n=39,treated with denixit for 6 weeks）.HAMA and HAMD were used to assess the clinical efficacy,and the side effects were evaluated by TESS.Results At the end of the 6th week,the total effective rate was 92.31% in the study group and 66.67% in the control group,with statistically significant difference between the two groups（χ2=4.27,P0.05）.TESS also showed statistically significant difference between the two groups（t=5.75,P0.05）.The side effects in the study group were significantly fewer than that in the control group.Conclusion Venlafaxlna sustained-release tablet was an antipsychotic drug with better efficacy and tolerance,with less side effects.